Head to Head Analysis: iRadimed (NASDAQ:IRMD) & Organigram Global (NASDAQ:OGI)

iRadimed (NASDAQ:IRMD) and Organigram Global (NASDAQ:OGI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

92.3% of iRadimed shares are held by institutional investors. Comparatively, 34.6% of Organigram Global shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 0.1% of Organigram Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares iRadimed and Organigram Global”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$86.34 million	12.89	$22.48 million	$1.79	48.61
Organigram Global	$309.18 million	0.43	-$17.70 million	$0.46	2.06

iRadimed has higher earnings, but lower revenue than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for iRadimed and Organigram Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0	3	2	1	2.67
Organigram Global	0	1	2	0	2.67

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 37.91%. Given iRadimed’s higher probable upside, equities analysts plainly believe iRadimed is more favorable than Organigram Global.

Profitability

This table compares iRadimed and Organigram Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Organigram Global	28.14%	-13.39%	-8.67%

Risk & Volatility

iRadimed has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Summary

iRadimed beats Organigram Global on 10 of the 13 factors compared between the two stocks.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.